Until now, systemic biomarkers to measure exercise effects on brain function and that link to relevant metabolic responses were lacking. A study shows a memory biomarker, myokine Cathepsin B (CTSB), increased in older adults following a 26-week structured aerobic exercise training. The positive association between CTSB and cognition, and the substantial modulation of lipid metabolites implicated in dementia, support the beneficial effects of exercise training on brain function and brain health in asymptomatic individuals at risk for Alzheimer’s.
A study released by Houston Methodist Sept. 10 in the Journal of Clinical Investigation takes researchers closer to developing a uniform, universal COVID-19 antibody test. The multicenter collaboration tested alternative ways to measure COVID-19 antibody levels that’s faster, easier and can inexpensively be used on a larger scale to accurately identify potential donors for plasma therapy with the best chance of helping patients infected with SARS-CoV-2.
Dr. Luis Ostrosky, professor of infectious disease at McGovern Medical School at UTHealth, co-investigator of first Texas randomized trial for convalescent therapy for COVID-19, is available to discuss latest data and FDA’s hold on the emergency authorization of blood plasma…
Johns Hopkins researchers have received $35 million in funding from the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the Defense Health Agency, for two nationwide clinical trials to test the effectiveness of a convalescent blood plasma outpatient treatment. The treatment is a transfusion of a blood product from COVID-19 survivors that contains antibodies that may help the patient’s immune system fight the virus.
Researchers at University of California San Diego School of Medicine and UC San Diego Health have launched a clinical trial to assess the safety and efficacy of convalescent plasma (CP) to prevent COVID-19 after a known exposure to the virus.
High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS).
A clinical trial now underway is looking at whether blood plasma donated by people recovered from 2019 coronavirus disease (COVID-19) could be used to treat other people with the pandemic virus.
The FDA’s announcement Friday to approve convalescent serum therapy as a large-scale clinical trial opened the door for more patients to receive the potentially life-saving gift of a donor’s plasma.